This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Xtandi

Astellas Pharma, Inc.

Drug Names(s): enzalutamide, MDV3100

Description: MDV3100 is an androgen-receptor antagonist. It inhibits androgens, like testosterone, from binding to the androgen receptor. It also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex.

Companion Diagnostics:
- Enzalutamide Companion Diagnostic

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

MDV3100 was originally developed by Medivation.

Astellas and Medivation
In October 2009, Astellas and Medivation announced that they have entered into a global agreement to develop and commercialize MDV3100. Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.

Astellas and...See full deal structure in Biomedtracker

Partners: Pfizer Inc. Tecnofarma International Ltd. Royalty Pharma AG


Xtandi News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug